
    
      Subjects participating in this study will be followed from time of roll-over from the parent
      GM T protocol until 15 years after the last GMT infusion, withdrawal of consent, lost to
      follow-up, or death, whichever occurs first. Both local and central laboratory evaluations
      and safety assessments will be conducted during this trial. In addition, pediatric subjects
      will be monitored for growth, development and sexual maturity.

      Stage 5 per Tanner Staging Criteria must be reached prior to study discontinuation.
    
  